Eribulin

BNF:

8.1.5

Status:

Do Not Prescribe (DNP), Red

Decision Date:

January 2017

Comments

RED:^1,2,3: NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens.

DO NOT PRESCRIBE (DNP)⁶: NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen. (Decision date - April 2018)  

NHSE are the responsible commissioner for this drug.

Black Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again